Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-Dose IV Oritavancin in Pediatric ABSSSI
2024-516385-10-00Phase 2Completed
- Sponsor
- Melinta Therapeutics
- Start
- Nov 2024
- Modality
- Small Molecules, Peptides
- Countries
- 9
01
Overview
Phase 2, randomised, single-blind trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Melinta Therapeutics. Primary endpoint: Safety assessment of ORBACTIV and KIMYRSA in pediatric populations. Started Nov 2024; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on 2024-516385-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516385-10-00.